Ebola booster study pulled before it began
NCT ID NCT05959421
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to check how long the Ebola vaccine (ERVEBO) protects people who might be exposed at work, like lab workers or healthcare staff. It also planned to see if a booster shot could extend that protection. However, the trial was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ebola vaccine (VSV-EBOV, brand name ERVEBO)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA VACCINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bernhard Nocht Centre for Clinical Trials (BNCCT)
Hamburg, 20359, Germany
-
University Hospital Frankfurt (KGU)
Frankfurt, 60590, Germany